Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer

Tonyali, Onder; Benekli, Mustafa; Berk, Veli; Coskun, Ugur; ÖZKAN, METİN; Yildiz, Ramazan; Ucgul, Emel; Sevinc, Alper; Uncu, Dogan; Demirci, Umut; Buyukberber, Suleyman

doi:10.1007/s00432-013-1409-1

Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer

Tonyali O., Benekli M., Berk V., Coskun U., ÖZKAN M., Yildiz R., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.139, sa.6, ss.981-986, 2013 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 139 Sayı: 6
Basım Tarihi: 2013
Doi Numarası: 10.1007/s00432-013-1409-1
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.981-986
Erciyes Üniversitesi Adresli: Evet

Özet

Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC). This retrospective study evaluated the efficacy and toxicity of trastuzumab and paclitaxel plus capecitabine in the first-line therapy for patients with HER2-positive MBC.